TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05369000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-1207
Description: In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-1207
Description: In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-1207
Description: In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-1207 plus Pembrolizumab
Description: Pembrolizumab will be administered via intravenous infusion
Study: NCT05341726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE Intervention
Description: BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
Study: NCT04555161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aria CV Pulmonary Hypertension System
Description: The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
Study: NCT04059640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBand FIX8 Open Hernia Mesh Fixation Device
Description: Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant.
Study: NCT05797168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5335
Description: IV Antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5335
Description: IV Antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib (AZD5305)
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Alkylating agent
Study: NCT06550076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 oral tablet
Study: NCT05370911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms
Study: NCT04870515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard lifestyle recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary instructions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete aerobic and strength/resistance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06396429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection; low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection; medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: blank preparation, participants received matching placebo.
Study: NCT05055323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrvinium Pamoate
Description: Given PO
Study: NCT06209138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline solution contains 0.9 percent sodium chloride (salt)
Study: NCT04731480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
Study: NCT04602598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 80 MG
Description: Zanubrutinib 80 MG for 24 weeks
Study: NCT06117254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Counseling
Description: Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
Study: NCT05784350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
Description: group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
Description: group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.
Study: NCT06117254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Counseling
Description: Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Counseling
Description: Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Description: Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Description: Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Microphones
Description: Remote microphone systems will be provided for use with hearing aids.
Study: NCT05327465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise
Description: Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
Study: NCT05506449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP®
Description: Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
Study: NCT06779019

Intervention type: DIAGNOSTIC_TEST
Intervention: LSCI
Description: LSCI evaluates at 2 timings:immediately after the mastectomy (prior to immediate reconstruction) and again following reconstruction (after the skin was sutured). The perfusion score was calculated by normalizing these values against the perfusion value of a control.

Intervention type: DIAGNOSTIC_TEST
Intervention: ICG (Indocyanine Green)
Description: Performed immediately after the mastectomy (prior to immediate reconstruction) .Perfusion scores were determined by comparing the fluorescence intensity of the target area to that of the non-surgical region on the contralateral chest wall.
Study: NCT06777563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychological counselling and health education
Description: This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
Study: NCT06423482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK bar
Description: The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium bar
Description: The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
Study: NCT06777563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychological counselling and health education
Description: This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
Study: NCT04910152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRD4 Inhibitor PLX51107
Description: Given PO
Study: NCT05326451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
Study: NCT06491030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Align PJK™ TLSO brace
Description: Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard of care postoperative instructions without a brace
Study: NCT05286827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
Study: NCT04837222

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05714683

Intervention type: DRUG
Intervention: Semaglutide
Description: All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Study: NCT05854550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apreo Implant Group
Description: One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
Study: NCT05222971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1,500 mg IV on Day 1~Every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib 300 mg twice daily~Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice daily~Every 4 weeks
Study: NCT04614441

Intervention type: DRUG
Intervention: OFEV®
Description: nintedanib

Intervention type: DRUG
Intervention: OFEV®
Description: nintedanib

Intervention type: DRUG
Intervention: OFEV®
Description: nintedanib
Study: NCT05058287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol 40Mg/Ml Suspension for Injection
Description: 40mg Depo-Medrol mixed with hemostatic matrix

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of sterile normal saline mixed with hemostatic matrix
Study: NCT06489041

Intervention type: GENETIC
Group type: OTHER
Intervention: Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx
Description: Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
Study: NCT05356104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide extended release
Description: 2mg once weekly via subcutaneous injection
Study: NCT05056844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CESM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT
Study: NCT06777563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychological counselling and health education
Description: This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Weeks of Ecological Momentary Assessment (EMA)
Description: The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Weeks of Ecological Momentary Assessment (EMA)
Description: The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 weeks of mobile health psychological support
Description: A total of 20 regular instant messages (e.g., via WhatsApp) personalised by baseline demographic characteristics (current pregnancy details, history of postpartum mental illness) and results of EMA will be sent to the participants in multi-media formats.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-guided telephone counselling booster
Description: A 45-minute telephone counselling based on CBT.
Study: NCT06269198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WARD-CSS
Description: Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded.
Study: NCT05797246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
Study: NCT05220332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart
Description: The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Money Smart
Description: The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
Study: NCT05334069

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study: NCT06141538

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.
Study: NCT04450368

Intervention type: DEVICE
Intervention: Sylvee
Description: The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
Study: NCT05056844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Agent
Description: Given iodine-based contrast agent IV